Eli Lilly and Co (LLY)
770.00
-1.12
(-0.15%)
USD |
NYSE |
May 17, 16:00
768.50
-1.50
(-0.19%)
Pre-Market: 05:44
Eli Lilly Cash from Operations (Annual): 4.240B for Dec. 31, 2023
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 4.240B |
December 31, 2022 | 7.586B |
December 31, 2021 | 7.366B |
December 31, 2020 | 6.500B |
December 31, 2019 | 4.837B |
December 31, 2018 | 5.524B |
December 31, 2017 | 5.616B |
December 31, 2016 | 4.851B |
December 31, 2015 | 2.965B |
December 31, 2014 | 4.458B |
December 31, 2013 | 5.735B |
December 31, 2012 | 5.305B |
December 31, 2011 | 7.234B |
December 31, 2010 | 6.857B |
December 31, 2009 | 4.336B |
December 31, 2008 | 7.296B |
December 31, 2007 | 5.154B |
December 31, 2006 | 3.976B |
Date | Value |
---|---|
December 31, 2005 | 1.914B |
December 31, 2004 | 2.870B |
December 31, 2003 | 3.647B |
December 31, 2002 | 2.071B |
December 31, 2001 | 3.662B |
December 31, 2000 | 3.732B |
December 31, 1999 | 2.620B |
December 31, 1998 | 2.630B |
December 31, 1997 | 2.400B |
December 31, 1996 | 1.991B |
December 31, 1995 | 1.825B |
December 31, 1994 | 1.532B |
December 31, 1993 | 1.517B |
December 31, 1992 | 1.484B |
December 31, 1991 | 1.255B |
December 31, 1990 | 1.474B |
December 31, 1989 | 1.033B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Annual) Range, Past 5 Years
4.240B
Minimum
2023
7.586B
Maximum
2022
6.106B
Average
6.500B
Median
2020
Cash from Operations (Annual) Benchmarks
Amgen Inc | 8.471B |
Biogen Inc | 1.547B |
Johnson & Johnson | 22.79B |
Vertex Pharmaceuticals Inc | 3.537B |
Viking Therapeutics Inc | -73.38M |